RestructuringJul 30, 2026, 04:13 PM
Fulcrum Discontinues Pociredir Program, Cuts 85% Workforce
AI Summary
Fulcrum Therapeutics announced the discontinuation of its pociredir program for sickle cell disease following FDA concerns, leading to the cessation of all research and development activities. The company approved a significant restructuring plan, reducing its workforce by 85% to preserve capital. Concurrently, Fulcrum has initiated a comprehensive review of strategic alternatives to maximize stockholder value, including potential mergers or asset sales. For the six months ended June 30, 2026, the company reported an increased net loss of $(45.070) million, reflecting impairment and restructuring charges.
Key Highlights
- Discontinued pociredir program due to FDA concerns, ceasing clinical development.
- Approved restructuring plan, reducing workforce by 85% (from 57 to 9 employees).
- Ceased all research and development activities following restructuring.
- Initiated comprehensive review of strategic alternatives, including merger or asset sale.
- Net loss increased to $(45.070) million for the six months ended June 30, 2026.
- Operating expenses rose to $51.496 million for the six months.
- Recorded $5.086 million impairment of long-lived assets and $4.318 million restructuring expenses.
- Cash, cash equivalents, and marketable securities totaled $318.840 million as of June 30, 2026.
Price Impact
More from FULC